U.S. markets close in 1 hour 29 minutes

Brain Scientific Inc. (BRSF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.0300-0.0100 (-0.96%)
As of 11:01AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0400
Open1.2000
BidN/A x N/A
AskN/A x N/A
Day's Range1.0400 - 1.0400
52 Week Range0.1000 - 3.0100
Volume1,576
Avg. Volume3,238
Market Cap18.56M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1630
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Brain Scientific Selected as Finalist for 2020 Epilepsy Foundation Shark Tank Competition

    NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Brain Scientific Inc. (OTCQB:BRSF) (“Brain Scientific” or “Company”), a medical device and technology company offering products and solutions related to the brain including neurology, AI, and machine learning, announced today that its minimally invasive graphene electrode was selected as a finalist at the 2020 Epilepsy Foundation Shark Tank Competition. The Epilepsy Foundation’s Shark Tank Competition is an initiative to advance innovative ideas in epilepsy treatment and care. The winners of the 2020 Shark Tank Competition will receive international recognition and compete for awards to support the development and commercialization of an important new product, technology, or therapeutic concept to help people with epilepsy.Brain Scientific’s minimally-invasive graphene electrode idea was one of five finalists selected to present at the Shark Tank Competition. The Company is developing subcutaneous graphene electrode implants and graphene electrodes printed by 3D printers on the scalp that connect to a micro EEG signal processor to provide continuous seizure monitoring and uninterrupted data collection. The micro EEG signal processor is the size of a stamp and is printed by 3D technology on the scalp near the ear for maximum comfort. The goal of this disruptive technology will be to improve the quality of life for epilepsy patients and to offer health care providers an effective and novel monitoring tool. Brain Scientific has collaborated with GrapheneCA to make this project a reality.“We are extremely proud of having our under-the-skin EEG implant be recognized by the Shark Tank Competition,” said Boris Goldstein, Chairman of the Board. “Epilepsy as a whole is in dire need of a low cost and effective monitoring and data collection approach. Our technology aims to liberate epilepsy patients from having to waste time in hospital monitoring units.”The five finalists, including Dr. Goldstein on behalf of the Company, will present their discoveries at the Pipeline Conference, held virtually on August 27. Brain Scientific’s technology utilizes printed electrodes and connectors with on-the-scalp micro EEG processor, which increases the mobility of the technology. About Brain Scientific Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. Brain Scientific’s proprietary, clinical-grade neurological diagnostic devices are powered by machine learning algorithms that utilize big data analysis to optimize efficacy in diagnosis and patient care. To learn more about our corporate strategy, devices or for investor relations please visit www.brainscientific.com or email us at info@brainscientific.com.About Shark Tank Competition:The Epilepsy Therapy Project, an initiative of the Epilepsy Foundation, invited entries that represent the most innovative new ideas in epilepsy treatment and care for its annual Shark Tank Competition. The winner(s) of the 2020 Shark Tank Competition will receive international recognition and compete for awards totaling up to $200,000 to support the development and commercialization of an important new product, technology, or therapeutic concept to help people with epilepsy. For more information, please visit here.About GrapheneCA GrapheneCA is a privately owned, commercial-scale graphene-based materials manufacturer, and supply company headquartered in New York. It is dedicated to tackling the challenge of integrating graphene into real-world applications through the use of its own highly effective, scalable, and environmentally friendly production process. For more information, please visit https://grapheneca.comForward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek” or “project” or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand its business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.Irina Nazarova 9174351226 nazarova@memorymd.com

  • Brain Scientific Will Present the New Version of Disposable EEG Headset NeuroCap To Industry Professionals at ASET 2020 Virtual Annual Conference
    GlobeNewswire

    Brain Scientific Will Present the New Version of Disposable EEG Headset NeuroCap To Industry Professionals at ASET 2020 Virtual Annual Conference

    BRSF Brain Scientific Will Present the New Version of Disposable EEG Headset NeuroCap To Industry Professionals at ASET 2020 Virtual Annual ConferenceNEW YORK, Aug. 20, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Brain Scientific Inc. (OTCQB:BRSF) (“Brain Scientific” or “Company”), a neurology-focused medical device and software company, will participate in the ASET 2020 Virtual Annual Conference to present the latest version of NeuroCap™, the Company’s disposable EEG headset, to industry experts. This year, the ASET 61st Annual Conference will be presented in a virtual meeting setting on August 20-22. “We are glad that ASET 2020 found a way to hold the annual conference in this new virtual format. COVID-19 confirms the importance of our flagship product, a disposable NeuroCap that takes only five minutes to apply. All neurodiagnostic professionals are urged to follow sanitary techniques to avoid spreading COVID-19 through cross-contamination, and NeuroCap helps minimize cross-contamination and optimize sanitary practices. We are happy to present the newest version of NeuroCap at ASET 2020,” stated Irina Nazarova, Marketing Director of Brain Scientific.The Neurodiagnostic Society is the largest national professional association for individuals involved in the study and recording of electrical activity in the brain and nervous system. The Society’s ASET Annual Conference is attended by renowned EEG technicians, technologists and laboratory managers from all over the world.About Brain Scientific Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The Company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about our corporate strategy, devices or for investor relations please visit: www.brainscientific.com or email us at info@memorymd.com.About The Neurodiagnostic Society Annual Conference (ASET) The ASET Annual Conference is the premier education and exposition opportunity for Neurodiagnostic technologists in the country. It is the must-attend event for all neurodiagnostic professionals whether you are a technologist, laboratory manager, physician or representing a supplier. The Neurodiagnostic Society is the largest national professional association for individuals involved in the study and recording of electrical activity in the brain and nervous system. Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek” or “project” or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand its business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.Irina Nazarova 9174351226 nazarova@memorymd.comAttachment * BRSF

  • GlobeNewswire

    Brain Scientific's Expansion Relocates Its Headquarters to Bohemia, New York

    NEW YORK, NY, Aug. 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ Brain Scientific Inc. (OTCQB: BRSF), a neurology-focused medical device and software company, announced an expansion of their facilities via a headquarter relocation to Bohemia, New York in central Long Island. The additional space will give the Brain Scientific team the ability to conduct more comprehensive and advance in-house R&D and product development.Commenting on the planned headquarter move, Boris Goldstein, Chairman of the Board and Executive Vice President stated, “I believe this relocation of our headquarters to Bohemia is a strategic decision which will put us in a position of increased growth. The facility will house the space and staff needed to accommodate the demand of our existing devices as well as the development of new, innovative products.”The move coincides with several order placements in Q2 for Memory MD’s NeuroCap™, a hospital-grade, disposable, preconfigured EEG headset. These orders were linked to the need to limit contact between EEG technicians and patients to help eliminate the spread of COVID-19 in emergency rooms, ICUs, and clinical research.About Brain Scientific:Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The Company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about our corporate strategy, devices or for investor relations please visit: www.brainscientific.com or email us at info@memorymd.com.Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek” or “project” or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates, and assumptions, and are subject to several risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing or attract additional investors, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand its business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.Contact: Irina Nazarova 917-435-1226 nazarova@memorymd.com